The neuropathological hallmark of Alzheimer's disease (AD) is the co-occurrence of extracellular amyloid-β (Aβ) deposition and intraneuronal neurofibrillary changes composed of abnormal tau. Over the last decades, the concept emerged that neurofibrillary changes progress in a hierarchical manner from mesial temporal structures through the associative neocortex to primary sensory and motor fields, paralleling cognitive deterioration closer than Aβ. The observation that two patients (one cognitively normal, one with dementia) exhibited neurofibrillary changes closely overlapping as regards their entity and topographic distribution but differed for characteristics of Aβ deposition suggests that the latter may directly contribute in determining cognitive impairment in AD.

Divergent cognitive status with the same braak stage of neurofibrillary pathology : does the pattern of amyloid-β deposits make the difference? / E. Maderna, C. Cattaneo, F. Cacciatore, M. Catania, G. Di Fede, F. Tagliavini, G. Giaccone. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - 43:2(2015), pp. 375-379. [10.3233/JAD-140540]

Divergent cognitive status with the same braak stage of neurofibrillary pathology : does the pattern of amyloid-β deposits make the difference?

C. Cattaneo
Secondo
;
2015

Abstract

The neuropathological hallmark of Alzheimer's disease (AD) is the co-occurrence of extracellular amyloid-β (Aβ) deposition and intraneuronal neurofibrillary changes composed of abnormal tau. Over the last decades, the concept emerged that neurofibrillary changes progress in a hierarchical manner from mesial temporal structures through the associative neocortex to primary sensory and motor fields, paralleling cognitive deterioration closer than Aβ. The observation that two patients (one cognitively normal, one with dementia) exhibited neurofibrillary changes closely overlapping as regards their entity and topographic distribution but differed for characteristics of Aβ deposition suggests that the latter may directly contribute in determining cognitive impairment in AD.
Alzheimer's disease; amyloid-β; dispersion index; immunohistochemistry; neurofibrillary pathology; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Autopsy; Cognition Disorders; Disease Progression; Female; Humans; Neurofibrillary Tangles; Psychiatric Status Rating Scales; Psychiatry and Mental Health; Geriatrics and Gerontology; Clinical Psychology; Medicine (all)
Settore MED/43 - Medicina Legale
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
jad140540.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 392.36 kB
Formato Adobe PDF
392.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/426476
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact